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Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease
characterized by joint destruction. We have previously
reported an increase in interleukin (IL)-1b levels in the
serum of very early RA and in the synovial fluid (SF) of RA
patients. Therefore, the molecular mechanisms that regu-
late IL-1b activation, such as caspase-1, might play a rele-
vant role and have potential as therapeutic targets in RA.
Aim
The main goal of this study was to evaluate the state of
activation of caspase-1 in early polyarthritis and estab-
lished RA patients.
Patients and methods
Blood samples were collected from 12 untreated early
polyarthritis patients with less than 12 months of disease
duration, 12 methotrexate (MTX) treated established RA
patients and from 10 healthy controls. Caspase-1 activity
was assessed using the Caspase Assay kit.
Results
We found that both early polyarthritis and established
RA patients have higher levels of active caspase-1 than
healthy controls. Surprisingly, caspase-1 activation levels
in patient cells remain unchanged when cells were sti-
mulated with E. coli and ATP for 4h and 24h, whereas
in healthy control cells caspase-1 levels are significantly
increased after stimulation. We observed no significant
differences when comparing early polyarthritis with
established RA samples. However, in RA samples from
patients with higher disease activity (DAS28>5.2) the
active caspase-1 ratio is higher.
Conclusions
Our results suggest that leukocytes in both early poly-
arthritis and established RA patients have high baseline
levels of activated caspase-1, which cannot be signifi-
cantly increased by bacterial and ATP stimulation. We
also show that MTX treatment does not affect cas-
pase-1 activation. Altogether, our data supports the
hypothesis that caspase-1 is already activated in the
early phase of RA.
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